| 研究課題/領域番号 |
23K07800
|
|---|
| 研究種目 |
基盤研究(C)
|
| 配分区分 | 基金 |
|---|
| 応募区分 | 一般 |
|---|
| 審査区分 |
小区分53050:皮膚科学関連
|
|---|
| 研究機関 | 福岡大学 |
|---|
研究代表者 |
Loreto Feril 福岡大学, 医学部, 講師 (10435109)
|
|---|
| 研究期間 (年度) |
2023-04-01 – 2026-03-31
|
| 研究課題ステータス |
交付 (2023年度)
|
| 配分額 *注記 |
4,680千円 (直接経費: 3,600千円、間接経費: 1,080千円)
2025年度: 1,300千円 (直接経費: 1,000千円、間接経費: 300千円)
2024年度: 1,300千円 (直接経費: 1,000千円、間接経費: 300千円)
2023年度: 2,080千円 (直接経費: 1,600千円、間接経費: 480千円)
|
|---|
| キーワード | Ultrasound / Mechanical effect / Anti cancer effect / Therapeutic Ultrasound |
|---|
| 研究開始時の研究の概要 |
本研究では、低強度超音波(low-intensity ultrasound: LIUS)の全身照射用装置を開発し、悪性黒色腫を標的として、モデルマウスで、その転移・成長抑制効果の確認とその機序解明を目指す。さらにLIUS全身照射と免疫チェックポイント阻害薬(抗PD-1抗体、PD-L1抗体医薬)の併用により相乗的な抗腫瘍効果を発揮させる新規治療の開発を目指す。
|
| 研究実績の概要 |
Preliminary preparation for animal studies was meticulosly conducted. This involved testing of intraperitoneal injection of cancer cells, diligent of mice, careful design of in-vivo setup for ultrasound exposure, and preparing for the monitoring mechanisms.The safety of low-frequency ultrasound for drug delivery was evaluated in vivo. Specifically, pig skin tissue was irradiated with ultrasonic waves (frequency 47 kHz, sound intensity 1.29 W/cm2, diameter 8 mm, for 10 seconds). No apparent tissue damage occurred in the skin tissue under either continuous ultrasound irradiation for 10 seconds or 10 irradiations of 1 second each. This experiment suggests that low-frequency ultrasound is safe for living organisms.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
A prototype of the device planned for the first year was created. The safety of low-frequency ultrasound on animal skin was also confirmed. Although actual treatment experiments using tumor models could not be conducted, preparations were made for such experiments. Thus, the research is progressing relatively smoothly.
|
| 今後の研究の推進方策 |
The prototype created this year will be further improved and used for therapeutic experiments on tumor model animals. Furthermore, we will evaluate the improvement of the anti-tumor effect by combining it with antibody drugs.
|
